Ibrutinib treatment improves T cell number and function in CLL patients

Meixiao Long, … , Natarajan Muthusamy, John C. Byrd

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies.

METHODS. Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated.

RESULTS. Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLL patients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional CD4+ T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells.

CONCLUSIONS. Ibrutinib treatment increased the […]

Find the latest version:

http://jci.me/89756/pdf
Ibrutinib treatment improves T cell number and function in CLL patients

Meixiao Long,1,2 Kyle Beckwith,1,2,3 Priscilla Do,1,2,3 Bethany L. Mundy,1,3 Amber Gordon,1,3 Amy M. Lehman,2,4 Kami J. Maddocks,1,2 Carolyn Cheney,1 Jeffrey A. Jones,1,2 Joseph M. Flynn,1 Leslie A. Andritsos,1,2 Farrukh Awan,1,2 Joseph A. Fraietta,5 Carl H. June,5 Marcela V. Maus,6 Jennifer A. Woyach,1,2 Michael A. Caligiuri,1,2 Amy J. Johnson,1,2 Natarajan Muthusamy,1,2 and John C. Byrd1,2

1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA. 2Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA. 3Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4Biomedical Sciences Graduate Program, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA. 5Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 6Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies.

METHODS. Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated.

RESULTS. Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLL patients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional CD4+ T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells.

CONCLUSIONS. Ibrutinib treatment increased the in vivo persistence of activated T cells, decreased the Treg/CD4+ T cell ratio, and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms. These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers.

TRIAL REGISTRATION. ClinicalTrials.gov NCT01589302 and NCT02029443. Samples described here were collected per OSU-0025.

FUNDING. The National Cancer Institute.

Introduction

Chronic lymphocytic leukemia (CLL) patients are characterized by a profound immune suppression and perturbation of both innate as well as adaptive immunity (1), highlighted by increased susceptibility to infections, autoimmune conditions, and a higher incidence of secondary malignancies. In addition to global immunosuppression, CLL cells also evade immune destruction, owing to tumor-specific immune suppression via multiple mechanisms including expression of the immunosuppressive molecules CD200, HLA-G, and programmed death ligand 1 (PD-L1), among others (2–4). Malignant CLL B cells also phenotypically and functionally recapitulate the B10 and B10Pro regulatory B (Breg) cell types that produce IL-10, a major immunosuppressive cytokine (5). In addition to direct tumor immunosuppressive effects, CLL cells can also increase the number of regulatory T (Treg) cells that diminish cellular immune responses (6, 7). Moreover, CLL cells can induce IDO+/CD14+HLA-DR+ myeloid-derived suppressor cells (MDSCs), which inhibit T cell responses both directly and indirectly.
through promoting Treg cell induction and expansion (8). Collectively, these observations highlight the importance of immune interactions in CLL and make this disease an ideal model to study systemic tumor-mediated immune suppression.

It has been well established that the T cell compartment in CLL patients is dysfunctional. CLL T cell subsets are skewed toward a terminally differentiated phenotype, with significant reduction in naïve T cells and expansion of effector memory/effector T cells (9). CLL patient T cells also demonstrate features of pseudo-exhaustion, with significant upregulation of checkpoint molecules and exhaustion markers such as programmed death 1 (PD-1), CTLA-4, CD160, CD244, and CD57 (9, 10). These phenotypic changes are closely associated with profound functional defects including reduced cytotoxic capacity of CD8+ T cells and defective immunologic synapse formation (9). A shift in the balance between Th1, Th2, and Th17 immune subsets in CLL patients may also be an important factor in driving disease progression, and the T cell response in CLL patients is skewed toward Th2 polarization (11). Studies in CLL patients have also shown that a decrease in IL-17-producing T cells is associated with Treg cell expansion and disease progression (12–14), while increased Th17 cell numbers correlate with improved overall survival (15). To date, success in therapeutically enhancing cell-mediated immunity in CLL has been limited. Lenalidomide has favorable immune-modulating properties in T cells in CLL patients via downregulation of the lymphoid transcription factor IKZF1 through a cereblon-dependent mechanism, and can promote durable, sustained complete remissions in 50% or more of patients receiving this treatment (16). However, lenalidomide in this setting also can produce significant morbidity and sometimes fatal outcome from early-onset tumor flare.

New to the field of B cell cancer therapy are agents that irreversibly target Bruton's tyrosine kinase (BTK) such as ibrutinib, which yields high response rates and durable remissions in patients with CLL. Although data in humans are lacking, multiple reports document the T cell effects of ibrutinib in mouse models (17–21). Our group recently reported that ibrutinib irreversibly inhibits IL-2-inducible T cell kinase (ITK), leading to enhanced Th1 response in vitro and in vivo (21). In a CLL mouse model of bacterial infection, ibrutinib treatment led to a more than 2-fold increase in expansion of Th1 pathogen-specific T cells and corresponding suppression of Th2 immunity (21). Ibrutinib treatment also leads to a shift in macrophages toward a Th1-supportive phenotype and increases CD8+ T cell tumor infiltration in a mouse model of pancreatic cancer (22).

Recently, our group demonstrated that T cells isolated from CLL patients prior to starting ibrutinib expand ex vivo chimeric antigen receptor (CAR) T cells poorly, whereas those derived during treatment expand significantly better (23). Ruella et al. also reported that addition of ibrutinib to anti-CD19 CAR T cells improves responses against mantle cell lymphoma (24). Furthermore, it has been reported that in mouse lymphoma models ibrutinib enhances T cell-dependent antitumor immune responses and further potentiates the efficacy of immune checkpoint blockade (17, 18). Immune modulatory effects have been preliminarily reported with the BTK inhibitor acalabrutinib (ACP-196), which also demonstrates promising clinical activity in CLL (25). However, unlike ibrutinib, acalabrutinib lacks inhibitory activity against the BTK-related kinase ITK. Clinically, this raises the question of whether more selective BTK inhibition will promote effective immune modulation and avoid the off-target effects observed with ibrutinib.

Here, we comprehensively studied the effects of ibrutinib on T cells in vivo and the ability of this agent to modulate the immunosuppressive capacity of CLL cells, and compared the results to those achieved with acalabrutinib. Our results indicate that while both agents diminish tumor-mediated immune suppressive molecules, ibrutinib has unique immune-modulating capability in promoting expansion of chronically activated T cells by diminishing activation-induced cell death.

**Results**

Ibrutinib treatment increases numbers of both CD4+ and CD8+ T cells via a BTK-independent mechanism. We analyzed serial samples from 19 CLL patients who received ibrutinib treatment on a serial blood procurement study, OSU-0025. Not all experiments were performed on each patient’s serial sample; therefore, the actual n for each experiment was less than 19. We first evaluated the absolute numbers of T cells of various subsets in CLL patients during the course of ibrutinib therapy. As shown in Figure 1A (n = 18), a significant increase in total CD4+ and CD8+ T cell numbers was observed following ibrutinib treatment (approximately 3-fold by 8 weeks, or the beginning of cycle 3; P < 0.01 for both CD4+ and CD8+ T cells). Both CD4+ and CD8+ T cells were further categorized into naive (CD45RACCR7+), central memory (T-CM; CD45RA CCR7+), effector memory (T-EM; CD45RA CCR7+), and CD45RA– effector memory T (T-EMRA) cells (CD45RA CCR7-) (Figure 1A). The T-EMRA cell subset is considered to consist of more terminally differentiated effector memory/effectort cells (26). Among the different T cell subsets, the increase in total cell number was most prominent in the T-EMRA and T-EM compartments, whereas in the naive and T-CM subsets, the increase was more modest and not significant at several time points examined. For example, CD4+ T-EMRA cell numbers increased by more than 3-fold (from 0.055 × 10^3 to 0.18 × 10^3/μl) 8 weeks into treatment (beginning of cycle 3), while naive T and CD4+ T-CM cell numbers increased by about 2-fold at the same time point (from 0.065 × 10^3 to 0.147 × 10^3/μl for naive CD4+ T cells). This same pattern coincides with the frequencies of different T cell subsets, where the proportion of both CD4+ and CD8+ T-EM cells was modestly increased by cycle 6 of ibrutinib treatment (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI89756DS1). For example, the mean proportion of CD4+ T-EMRA cells increased from 5.1% to 7.3% (P < 0.05). In contrast, the proportion of naive and T-CM subsets was modestly but significantly reduced by cycle 6 of treatment in both CD4+ and CD8+ T cells (P = 0.006 for CD8+ T-CM cells and P = 0.001 for CD4+ T-CM cells; Supplemental Figure 1A). The reduced frequencies of both CD4+ and CD8+ T-CM subsets after ibrutinib treatment appears to be a result of a dilution effect from preferential expansion of the T-EM and T-EMRA subsets as shown in Figure 1A, versus loss of these cells during treatment.

One concern is that the increase in the circulating T cell numbers after ibrutinib treatment may merely reflect the release of T cells from the secondary lymphoid organs as opposed to true T cell expansion. To address this, we treated CLL-engrafted mice with ibrutinib and monitored peripheral blood T cell numbers.
before starting ibrutinib, and 2 days and 4 days after starting ibrutinib (Supplemental Figure 7). These time points correspond to the period when CLL cell numbers were transiently increased in peripheral blood after ibrutinib treatment (27). If ibrutinib causes translocation of T cells from secondary lymphoid organs to peripheral circulation like it does to CLL cells, we would notice an increase in T cell numbers in peripheral blood. However, we found no significant change in circulating T cell numbers before and after ibrutinib treatment, as shown in Supplemental Figure 7. Furthermore, we went on to question if ibrutinib can enhance the expansion of activated antigen-specific T cells using a mouse leukemia model. As shown in Supplemental Figure 8, we found that ibrutinib increased the number of tumor antigen–specific T cells in a secondary lymphoid organ (spleen) by approximately 2-fold.

To further examine if this effect on T cells was dependent or independent of BTK inhibition, we also examined similar parameters in CLL patients treated with acalabrutinib, a more selective BTK inhibitor that does not target other ibrutinib substrates such as ITK (25). Interestingly, we did not find similar increases in the cell numbers after acalabrutinib treatment (Figure 1B, n = 12). The frequency of CD4+ and CD8+ T cells trended up by cycle 6, which reflects the decrease in absolute lymphocyte count with

Figure 1. Ibrutinib but not acalabrutinib treatment of CLL patients increases total T cell numbers. (A) Absolute numbers of CD8+ (upper panel) and CD4+ (lower panel) T cells before and during ibrutinib treatment (n = 18). (B) Absolute numbers of CD8+ (upper panel) and CD4+ (lower panel) T cells before and during acalabrutinib treatment (n = 12). Each cycle is 4 weeks. Cycle 3 indicates samples obtained after 2 cycles (8 weeks into treatment), and cycle 6 indicates samples obtained after 5 cycles (20 weeks into treatment). T cells were differentiated into subsets based on expression of CCR7 and CD45RA: naive T cells (CCR7+CD45RA+), central memory T cells (CCR7–CD45RA–), effector memory T cells (CCR7–CD45RA+), and more differentiated effector memory T cells (T-EMRA; CCR7–CD45RA–). Differences were assessed using linear mixed-effects models. NS, not significant.
Figure 2. Ibrutinib treatment does not affect total numbers of stem memory T cells. (A) Gating strategy for stem memory T cells. Naive CD4+ T cells (CCR7+CD45RA+) expressing CD62L were selected for further analysis. Of these, CD95+CD122hi cells were defined as stem memory T cells. (B) Left: Representative plots showing stem memory T cells in samples from a healthy donor and a CLL patient. Right: Representative plots showing T-bet and eomesodermin (eomes) expression in naive CD8+ and CD4+ T cells from a healthy donor and a CLL patient. (C) Stem memory T cells before and during ibrutinib treatment. Left: Graphs showing absolute numbers (top) and percentages (bottom) of stem memory cells (n = 15). Right: Representative plots. Differences were assessed using linear mixed-effects models. NS, not significant.
AICD by reducing the upregulation of FASL (29). Here, we found that the upregulation of FASL expression in activated T cells after restimulation was indeed decreased by ibrutinib treatment (Supplemental Figure 2C), suggesting that ibrutinib ameliorates AICD by decreasing TCR activation–induced FASL upregulation. In contrast, we did not observe a similar protective effect against AICD with acalabrutinib at these same concentrations.

It has been reported that NK cells can also undergo apoptosis following activation via cytokine receptors (31). Ibrutinib targets such as ITK and BTK also play an important role in NK cell function and signaling processes (32, 33). Therefore, we investigated if acalabrutinib (Supplemental Figure 1B). Given that activated ITK-deficient T cells in murine systems have diminished activation-induced cell death (AICD) (28, 29), we hypothesized that the ITK inhibitory activity of ibrutinib, but not acalabrutinib, may explain this observation. We therefore examined the influence of these 2 agents on T cells ex vivo with extended activation. As shown in Supplemental Figure 2, A–C, activated T cells treated with ibrutinib exhibited a dose-dependent decrease in AICD. Upregulation of FAS ligand (FASL) by activated T cells and suicide by FAS-FASL interaction have been found to be an important mechanism for AICD (30). Moreover, ITK inhibition has been reported to impair AICD by reducing the upregulation of FASL (29). Here, we found that the upregulation of FASL expression in activated T cells after restimulation was indeed decreased by ibrutinib treatment (Supplemental Figure 2C), suggesting that ibrutinib ameliorates AICD by decreasing TCR activation–induced FASL upregulation. In contrast, we did not observe a similar protective effect against AICD with acalabrutinib at these same concentrations.

It has been reported that NK cells can also undergo apoptosis following activation via cytokine receptors (31). Ibrutinib targets such as ITK and BTK also play an important role in NK cell function and signaling processes (32, 33). Therefore, we investigated if

Figure 3. Treatment with BTK inhibitors significantly reduces PD-1-expressing cells in CD8+ T cell populations. Percentages of PD-1+ cells among different subsets of CD8+ T cells from CLL patients before and during treatment with (A) ibrutinib (n = 17) or (B) acalabrutinib (n = 10). Differences were assessed using linear mixed-effects models. NS, not significant.
Ibrutinib can also ameliorate AICD of NK cells utilizing an established assay system in which NK cells are costimulated with IL-2/IL-12 or IL-15/IL-12. Here, we found a similar protection by ibrutinib, but not acalabrutinib (Supplemental Figures 2 and 9).

Ibrutinib treatment does not compromise stem memory T cells localized in the naive T cell compartment. We next analyzed stem memory T (TSCM) cells, the long-lasting memory T cells that share many surface marker profiles with naive T cells. We further differentiated TSCM from naive T cells by staining for CD122 and CD95, as shown in Figure 2A. Interestingly, we found that CLL patients have more (>10%) TSCM cells within the naive T cell gate (Figure 2B). This differs from healthy donors, who usually have less than approximately 1%-2% of TSCM cells among the naive T cell gate (34). T-bet and eomesodermin are established Th1 differentiation markers (35). As expected, we found that few naive T cells from healthy donors express these markers (Figure 2B). However, a significant percentage of naive T cells (more than 10% naive CD4+ cells) from CLL patients express T-bet or eomesodermin. Therefore, a significant percentage of naive (CCR7+CD45RA+) T cells from CLL patients express T-bet or eomesodermin. We found that in patients receiving ibrutinib, the absolute number of TSCM cells was increased by cycle 3 and was not significantly changed by cycle 6 (Figure 2C, n = 15).

Frequencies of PD-1- and CTLA-4-positive T cells are significantly reduced after ibrutinib treatment. A key feature of T cells from CLL patients is the high percentage of cells expressing checkpoint inhibitor molecules such as PD-1 (Supplemental Figure 6). As ibrutinib rescues AICD of T cells, it is possible that these rescued cells may express a higher level of exhaustion markers that would suggest less immunologic potential. We therefore examined these markers in different T cell subsets before and after ibrutinib treatment. We found no significant changes in CD244, CD160, or CD57 after ibrutinib treatment (data not shown). However, the percentages of PD-1-positive cells among total CD8+ (Figure 3A, n = 17) and total CD4+ (Supplemental Figure 3A, n = 17) T cells were significantly reduced. The decrease in PD-1 was statistically significant by cycle 3 for CD8+ T cells (P = 0.001), and by cycle 6 for both CD4+ (P = 0.001) and CD8+ (P < 0.001) T cells. We also noticed that although PD-1 positivity was reduced in all the T cell subsets among both CD4+ and CD8+ T cells, the reduction was most dramatic in the T-EM compartment (Figure 3A and Supplemental Figure 3A). CD27 was downregulated in the more differentiated effector T and T-EM cells, prompting us to further differentiate the T-EM and T-EMRA cells into CD27+ versus CD27− populations. We did not find significant differences in the distributions of CD27+ and CD27− T cell subsets. However, for CD4+ T cells, the CD27+ T-EM and T-EMRA cells showed a statistically significant reduction in PD-1 after ibrutinib treatment (P < 0.001), while their CD27− counterparts did not (Supplemental Figure 3).

In our serial samples we were able to detect CTLA-4 expression by intracellular staining (Figure 4A and Supplemental Figure 4A, n = 18). We again detected a significant reduction in intracellular CTLA-4+ cells among both CD4+ T cells (Figure 4A; P < 0.001 for both cycle 3 and cycle 6) and CD8+ T cells (Supplemental Figure 4A; P < 0.01 for both cycle 3 and cycle 6), with the reduction being more dramatic in CD4+ T cells. Cells from patients treated with acalabrutinib showed similar patterns of change in PD-1 expression (Figure 3B and Supplemental Figure 3B, n = 10). Acalabrutinib treatment also reduced CTLA-4 expression on T cells (Figure 4B and Supplemental Figure 4B, n = 9), suggesting that ibrutinib affects PD-1 and CTLA-4 expression in T cells indirectly by inhibiting BTK.

Ibrutinib treatment does not significantly change T cell polarization. We previously reported that ibrutinib enhances Th1 polarization in vitro and in vivo in murine models. To study T cell polarization in human CLL patients, we restimulated peripheral blood mononuclear cells (PBMCs) from ibrutinib-treated patients with PMA/ionomycin and assessed their cytokine production pro-
Ibrutinib decreases the Treg/CD4+ T cell ratio but not absolute number of CD25+Foxp3+ Treg cells. In vitro experiments have shown enhanced differentiation toward Foxp3+ Treg cells by ITK-deficient conventional CD4+ T cells (36). Therefore, we sought to determine how ibrutinib treatment in human CLL patients affects Treg cells in vivo. Treg cells were identified as CD4+CD25+Foxp3+ cells (Figure 6A). We found an approximately 2-fold reduction in the percentage of CD25 Foxp3+ Treg cells among CD4+ T cells by cycle 6 (P < 0.001) that persisted to cycle 6 (P < 0.001) of ibrutinib treatment (Figure 6B, n = 18). However, this reduction in the Treg/CD4+ T cell ratio was associated with an increase in the absolute number of CD4+ T cells and the total number of Treg cells remained unchanged (Figure 6B). In acalabrutinib-treated patients, the number of CD4+CD25+Foxp3+ Treg cells and the Treg/CD4+ T cell ratio was not significantly changed (Figure 6C, n = 11).

Ibrutinib downregulates immunosuppressive molecules CD200 and BTLA on CLL cells. CLL cells have been reported to express a variety of immunosuppressive ligands; we therefore evaluated the expression levels of these immunosuppressive molecules in CLL cells before and after ibrutinib treatment. The surface expression of PD-L1, HLA-G, and CD276 was low in general, and we did not detect a significant change in their expression in CLL cells after ibrutinib treatment (data not shown). However, CD200 expression was significantly reduced as early as cycle 3 of ibrutinib treatment, and this reduction persisted through cycle 6 (P < 0.001 for both; Figure 7A, n = 18). BTLA expression was not significantly changed in T cell subsets (data not shown), while significant reduction in CLL cells was observed (P < 0.001 for both, n = 16).

Similar reductions were observed in samples from patients treated with acalabrutinib (Figure 7B, n = 12), indicating a BTK-dependent mechanism for these changes.

The capacity of CLL cells to make IL-10 after prolonged B10Pro conditioning is impaired after ibrutinib treatment. It has been reported that CLL cells share phenotypic and functional features with Breg cells and can produce IL-10 after in vitro stimulation under B10 (5-hour stimulation) or B10Pro (48-hour stimulation) conditions (5). Activation through the BCR, TLRs, and CD40 is required for production of IL-10 by B cells or CLL cells (37). As BTK is involved in signal transduction of all these receptors (38, 39), we hypothesized that BTK inhibition may affect IL-10 production in CLL cells. We detected significant IL-10 production by CLL cells after a brief in vitro stimulation under B10 conditions in less than half of the CLL patient
samples, in agreement with previous reports (5), and we did not detect significant changes in the frequency of these rare malignant B10 cells after ibrutinib treatment (Figure 8, A and B, n = 13). However, by stimulating cells under B10Pro conditions, we were able to induce IL-10 production by CLL cells from most of the samples tested. Interestingly, after ibrutinib treatment, CLL cells showed a dramatically reduced capacity to secrete IL-10 after being stimulated under B10Pro conditions (P < 0.0001). This reduction was observed as early as cycle 3 of ibrutinib treatment, when the majority of the patients studied still showed transient lymphocytosis (Figure 8B, n = 18). Samples from patients treated with acalabrutinib showed similar results (Figure 8C, n = 10 for B10 conditions, n = 12 for B10Pro condition), indicating that the reduced capacity of CLL cells to make IL-10 following ibrutinib treatment is from BTK inhibition.

Discussion
Numerous studies in mice have reported the favorable immune-modulating effect of ibrutinib that likely occurs through multiple mechanisms (17–21). Here, in what we believe is the first comprehensive human study of ibrutinib’s effects on T cells, we identified significant increases in both CD4+ and CD8+ T cell numbers following ibrutinib treatment in CLL patients. These T cells, while increased in number following ibrutinib treatment, lack the typical immunophenotypic features of CLL-exhausted T cells, as evidenced by significantly lower PD-1 and intracellular CTLA-4 expression. Unlike other immune-modulating agents such as IL-2 that expand Treg cells, ibrutinib in fact decreases the Treg/CD4+ T cell ratio by selectively expanding conventional T cells. Separate from the favorable effects on T cells, ibrutinib also modulates the expression of several immune-suppressive molecules on/in CLL cells including CD200, BTLA4, and IL-10. Acalabrutinib is a second-generation, selective BTK inhibitor. As shown in Supplemental Table 1, while ibrutinib has comparable IC50 for BTK and ITK, acalabrutinib has virtually no affinity for ITK (25, 40). Our pharmacologic studies in patients clearly differentiate ibrutinib from the more selective BTK inhibitor acalabrutinib in its ability to inhibit AICD via ITK inhibition. Collectively, this and previous studies show that ibrutinib represents a potentially novel T cell immune-modulating agent, and our data clearly differentiate it from other immunotherapeutics used in cancer.

The remarkable finding of our work is the notable increase of both CD4+ and CD8+ T cells in patients receiving ibrutinib. This T cell expansion is unlikely to be caused by BTK inhibition, as we did not observe increased T cell numbers in patients treated with the more selective BTK inhibitor acalabrutinib that lacks ITK inhibitory activity. While discerning the mechanism of T cell expansion in vivo in CLL patients is not possible, we provide evidence that ibrutinib treatment of activated T cells diminishes AICD by targeting ITK, a finding also reported in murine models of ITK deficiency (29). ITK has been demonstrated to be involved in TCR-induced upregulation of FASL and AICD of T cells (28, 29). In vitro, ITK-deficient T cells have been found to have impaired proliferation (41), whereas in vivo, activated ITK+ T cells survived to a much greater degree than normal T cells, leading to a greater accumulation (28). Targeting ITK with kinase inhibitors showed a similar pattern. In vitro, ITK inhibitors inhibit IL-2 secretion and T cell proliferation (42), whereas in vivo the ITK inhibitor was found to reduce AICD, leading to a 2- to 3-fold increase in activated T cell numbers (29).

In contrast to our findings, Niemann et al. (43) recently reported that ibrutinib treatment led to a decrease in circulating T cell numbers in CLL patients that paralleled the progressive decrease of CLL tumor burden and normalization of T cell counts in most patients. This difference might be best explained by the impact of CLL tumor burden. It has been postulated that CLL cells promote chronic stimulation of T cells and lead to an exhaustion phenotype by inducing a CLL-specific immune response, or by modifying the T cell response to chronic infections including cytomegalovirus (CMV) (10, 44). In either case, CLL cells cause chronic activation of T cells, and it is the activated T cells, but not resting T cells, that are susceptible to AICD and can be rescued by ibrutinib. Therefore, this effect on T cell numbers by ibrutinib is likely only to be seen in patients who

### Table 1. Clinical characteristics of the studied patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis</td>
<td>Mean (SD) 54 (11.5)</td>
</tr>
<tr>
<td></td>
<td>Median 53</td>
</tr>
<tr>
<td>Age starting ibrutinib</td>
<td>Mean (SD) 64 (8.6)</td>
</tr>
<tr>
<td></td>
<td>Median 64</td>
</tr>
<tr>
<td></td>
<td>Male sex 11</td>
</tr>
<tr>
<td>Rai stage at ibrutinib treatment</td>
<td>0–2 1</td>
</tr>
<tr>
<td></td>
<td>3 1</td>
</tr>
<tr>
<td></td>
<td>4 17</td>
</tr>
<tr>
<td>Number of prior therapies</td>
<td>0 0</td>
</tr>
<tr>
<td></td>
<td>1 6</td>
</tr>
<tr>
<td></td>
<td>2 4</td>
</tr>
<tr>
<td></td>
<td>3–4 4</td>
</tr>
<tr>
<td></td>
<td>5 or more 5</td>
</tr>
<tr>
<td>Prior allogeneic transplant</td>
<td>2</td>
</tr>
<tr>
<td>Cytogenetics</td>
<td>Del(13q) 13</td>
</tr>
<tr>
<td></td>
<td>Del(11q) 9</td>
</tr>
<tr>
<td></td>
<td>Del(17q) 4</td>
</tr>
<tr>
<td></td>
<td>Trisomy 12 0</td>
</tr>
<tr>
<td></td>
<td>Complex karyotype 8</td>
</tr>
<tr>
<td>IgH mutation status, unmutated,</td>
<td>14, 5, 0</td>
</tr>
<tr>
<td>mutated, unknown</td>
<td></td>
</tr>
<tr>
<td>Bone marrow involvement at the time</td>
<td>88.1 (70–99)</td>
</tr>
<tr>
<td>of ibrutinib therapy, % (range)</td>
<td></td>
</tr>
<tr>
<td>ALC (baseline before ibrutinib)</td>
<td>Mean (SD) 46.5 (40.1)</td>
</tr>
<tr>
<td></td>
<td>Median 29.9</td>
</tr>
<tr>
<td>ALC (cycle 3 day 1)</td>
<td>Mean (SD) 122.6 (66.9)</td>
</tr>
<tr>
<td></td>
<td>Median 99.1</td>
</tr>
<tr>
<td>ALC (cycle 6 day 1)</td>
<td>Mean (SD) 60.9 (52.9)</td>
</tr>
<tr>
<td></td>
<td>Median 47.6</td>
</tr>
</tbody>
</table>
The influence of ibrutinib in CLL patients also has direct positive influence on the immunosuppressive capacity of the primary tumor cells. In this study, we confirmed that CD200 and BTLA are significantly downregulated on the surface of CLL cells as early as cycle 3 of ibrutinib treatment. While the function of BTLA on CLL cells is uncertain, CD200 regulates both innate and adaptive immunity and plays a key role in both tumor-specific and global immune suppression in CLL patients (4). Moreover, CD200 expression on tumor cells has been found
to promote the expansion of Treg cells, and CD200 blockade significantly decreases Treg cell numbers (6, 7, 49). Ibrutinib was shown to promote the expansion of Treg cells, and CD200 blockade which are also CD5+ B cells and are enriched with B10 (~30%) showed a more severe reduction in the numbers of B1a cells (53), (52). In support of this, mice with BTK deficiency (XID mice) were shown to have a more severe reduction in the numbers of B1a cells (53). Therefore, BTK inhibition may reduce the frequency of B10/B10Pro cells, which can express IL-10 after prolonged in vitro stimulation, and similar findings with acalabrutinib suggest this is a BTK-dependent effect. To induce IL-10 expression in B10/B10Pro cells, stimulation via BCR, TLR4/9, and CD40L are required (5). BTK is involved in signaling transduction of all these receptors (39, 50, 51). Recently, it was found that the chemokine CXCL12 enhances IL-10 production in CLL cells via the CXCR4/STAT3 pathway (38), and BTK inhibition was reported to impair CXCR4 surface expression and signaling in CLL cells (52). In support of this, mice with BTK deficiency (XID mice) showed a more severe reduction in the numbers of B1a cells (53), which are also CD5+ B cells and are enriched with B10 (~30%) and B10Pro (30%-40%) cells (53). Therefore, BTK inhibition may reduce the frequency of B10Pro-like CLL cells via 2 mutually nonexclusive mechanisms: by directly inhibiting the IL-10 production in CLL cells, and/or by selectively depleting B10Pro-like CLL cells. IL-10 is a major immunosuppressive cytokine that can be produced by multiple cell types. Surprisingly, it has been found that B cells are actually a dominant source of IL-10 in vivo in both naive and immune system–activated mice (54). Secretion of IL-10 by CLL cells could be triggered by infections or host inflammatory responses in CLL. Given the significantly elevated number of malignant B cells in CLL patients, production of IL-10 by even a small fraction of the tumor cells could cause significant immune suppression (5). Endogenous B10/Breg cells were shown to inhibit CD20 mAb–induced lymphoma regression by secreting IL-10 and inhibiting mAb-mediated monocyte activation (55). CLL cell IL-10 production was also found to significantly inhibit monocyte activation (5). Therefore, by reducing the IL-10 production by CLL cells, ibrutinib treatment could lead to relief of CLL-induced immune suppression. Moreover, as B10/B10Pro cells share many phenotypic and functional features with CLL cells, it is possible that ibrutinib treatment also depletes these immunosuppressive cells or impairs their function.

Our study includes comparative data from CLL patient samples obtained at matched time points during treatments with either an irreversible ITK/BTK inhibitor or more selective BTK inhibitor. Although descriptive, these experiments identify effects such as expansion of effector T cells, increased proportion of Th17-producing cells, and distinct changes in CTLA-4 intracellular expression between CD4+ and CD8+ subsets that are likely attributable to alternative, non-BTK targets such as ITK that are inhibited by ibrutinib but not acalabrutinib. We also provide in vitro evidence that ibrutinib but not acalabrutinib prevents AICD of activated T cells and NK cells. In contrast, decreased expression of surface PD-1 on CD4+ and CD8+ T cells and intracellular CTLA-4 on CD4+ T cells was observed with both agents, implicating BTK as an indirect factor in this change. This may be through modulation of immune-suppressive molecules (CD200, IL-10, and others) on CLL tumor cells, which are impacted by both agents, and further studies to understand these effects are ongoing. Due to the smaller sample size for acalabrutinib-treated patients available for analysis, some of the negative findings on acalabrutinib were underpowered. For example, there is also a trend towards a decrease in the percentage of Treg cells after acalabrutinib treatment, and with increased sample size, this could be a statistically significant difference — albeit more modest compared with the difference observed in ibrutinib-treated samples. Nonetheless, our data presented here identify ibrutinib and acalabrutinib as distinctly different immunomodulating agents. Despite potential added toxicity with ibrutinib due to alternative target inhibition, our data show improved immune modulation in vivo with this agent compared with acalabrutinib and support its use in combination with other immune therapies.

In summary, by studying CLL patients treated with ibrutinib, we have identified its superior immunomodulatory effects by virtue of being a less specific inhibitor of BTK. Ibrutinib induces significant increases in T cell numbers that are not achieved by a more selective BTK inhibitor. The underlying mechanism is likely to be ITK inhibition that leads to the rescue of chronically stimulated T cells from AICD. Our data therefore provide support for ibrutinib therapy as an ideal cellular immune-modulating agent for CLL and potentially other types of hematologic and solid cancers. For example, ibrutinib can be incorporated as part of cellular immune therapy. In vivo persistence and expansion of antigen-specific T cells is the most critical determining factor for the success of adoptive immunotherapy with tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cells (56). Expanding such cells with systemic administration of IL-2 is toxic and may have deleterious effect on the long-term persistence of antitumor immunity (46). IL-2 also leads to preferential expansion of Treg cells (57). Preconditioning with lymphocyte depletion enhances homeostatic proliferation and depletes host Treg cells. However, it also carries along significant
boost the persistence of tumor-specific T cells. Of note, checkpoint blockade of CTLA-4 has been found to expand functional Treg cells (59). Ibrutinib enhances persistence/expansion of activated T cells and shows the following desirable qualities: (a) it has no deleterious effects on the T-CM or naive T cells, (b) it does not cause collateral expansion of the Treg cells, and (c) it partially reverses the exhausted T cell phenotype by reducing the expression of PD-1 and CTLA-4. Together, these findings provide further rationale for use of ibrutinib as an adjuvant for expansion of TILs or CAR-T cells, as our recent data demonstrated (23).

Methods

Detailed protocols are provided in the supplemental methods.

Patient samples. All patients provided written informed consent to provide material as part of an IRB-approved trial. Blood samples were collected before treatment and at completion of 2 months (cycle day 1) and 5 months (cycle day 1) of ibrutinib or acalabrutinib treatment from CLL patients enrolled in our blood collection study OSU-0025 that allows serial collection of samples at a monthly interval in leukemia patients. Samples described here are from NCT01589302 and NCT02029443 (clinicaltrials.gov). PBMCs were isolated from blood samples by density gradient centrifugation using Ficoll. PBMCs were then washed twice, resuspended in freezing medium containing 10% DMSO, and were stored in a liquid N2 cryopreservation system. Patient characteristics are shown in Table 1. Details of patient information are shown in Supplemental Table 2.

Mice, cell line, and antibodies. All animal experiments were carried out under protocols approved by The Ohio State University Institutional Laboratory Animal Care and Use Committee. TCL-1-transgenic mice (on the C57BL/6 background) used for these experiments have been previously described (21). Breeding pairs were provided to our group as a gift from Carlo M. Croce (The Ohio State University). OT-1 TCR-transgenic mice were purchased from The Jackson Laboratory. C1498-OVA is a murine myeloid leukemia cell line (H-2b, C57BL/6 background) expressing the experimental surrogate antigen ovalbumin. It was provided by Bruce R. Blazer (University of Minnesota, Minneapolis, Minnesota, USA). All antibodies used are listed in Supplemental Table 3.

Statistics. Separate linear mixed-effects models were used to assess differences (cycles 3 and 6 vs. baseline) in cell number and percentage as well as mean fluorescence intensity (MFI) among the different subsets for patients treated with ibrutinib and acalabrutinib. Absolute cell number and MFI data were first log-transformed to reduce skewness and stabilize variances. An initial analysis was performed based on 17 patients treated with ibrutinib and 9 patients treated with acalabrutinib. Later, an additional 2 patients with ibrutinib and 4 patients with acalabrutinib were added to the original cohorts and the analysis was repeated. Results are shown for the updated data with a total of 19 ibrutinib patients and 13 acalabrutinib patients. A comparison of the original and updated results is provided in Supplemental Table 4. Not all experiments were performed on each patient’s serial sample; therefore, the actual n for each experiment was less than 19 and 13 for ibrutinib- and acalabrutinib-treated patients, respectively. All clinical-sample analyses were performed using SAS/STAT software, version 9.4 of the SAS System for Windows (SAS Institute Inc.). For the in vitro and animal experiments described Supplemental Figures 2, 7, and 8, a 2-tailed Student’s t test was used. A P value less than 0.05 was considered significant for all the experiments.

Study approval. The studies on human samples were reviewed and approved by The Ohio State University IRBs. All subjects provided appro-
priate prior informed consent to participate in the study. The respective studies on C57BL/6 WT, TCR-1-transgenic, and OT-1-transgenic animals were reviewed and approved by the IACUC at The Ohio State University.

**Author contributions**

ML contributed to the designing and performing of the experiments, data analysis, and writing the manuscript. KB, PD, CC, and AG helped sample processing and performing of the experiments. BLM and MAC designed and performed the NK cell ADCC experiments. AML performed the statistical analysis and interpretation of the data. KJM, JAJ, JMF, LAA, FA, and JAW contributed to provision of study materials/recruiting of patients. JAF, CHJ, MVM, MAC, AJJ, and NM critically reviewed the manuscript and helped with the interpretation of the data. JCB and NM designed the study, secured funding, directed the research, analyzed data, and had overall oversight of the trial and manuscript.

**Acknowledgments**

JAF acknowledges funding from the University of Pennsylvania during this study. This work was supported by the National Cancer Institute (NCI): T32CA009140 (JAF), K08166039 (MVM), P01 CA095426 (AJ, NM, JCB), K23 CA178183 (JAW), R35 CA198183 (JCB), R01 CA 177292 (JCB, AJJ), R01 CA197870 (JAW, AJJ), 5 K12 CA133250-08 (ML) and P30 CA016058 (MAC, JCB), as well as Michael and Judy Thomas, the D. Warren Brown Foundation, and the Four Winds Foundation.

Address correspondence to: John C. Byrd or Natarajan Muthusamy, The Ohio State University Comprehensive Cancer Center, 455 Wiseman Hall, 400 West 12th Avenue, Columbus, Ohio 43210, USA. Phone: 614.293.8330; Email: john.byrd@osumc.edu (J.C. Byrd); Phone: 614.685.2407; Email: raj.muthusamy@osumc.edu (N. Muthusamy).

---


12. Jadidi-Niaragh F, et al. Downregulation of the data. KJM, JAJ, JMF, LAA, FA, and JAW contributed to provision of study materials/recruiting of patients. JAF, CHJ, MVM, MAC, AJJ, and NM critically reviewed the manuscript and helped with the interpretation of the data. JCB and NM designed the study, secured funding, directed the research, analyzed data, and had overall oversight of the trial and manuscript.


